Piper Sandler Reiterates Overweight on Orchestra BioMed Hldgs, Raises Price Target to $10

Benzinga · 3d ago
Piper Sandler analyst Matt O'Brien reiterates Orchestra BioMed Hldgs (NASDAQ:OBIO) with a Overweight and raises the price target from $9 to $10.